Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The avian influenza virus hemagglutinin protein is a trimeric glycoprotein found on the surface of influenza viruses, acting as the primary protein responsible for viral entry into host cells[1][2][3][4][5]. Hemagglutinin mediates two essential steps: binding to sialic acid–containing receptors on host cells (receptor binding) and triggering the fusion of the viral envelope with the host cell membrane (membrane fusion) in response to the low pH of endosomes[1][3][4][5]. It is synthesized as an inactive precursor (HA0), which is later cleaved into HA1 and HA2 subunits required for fusion competence; avian influenza strains often have specific cleavage sites associated with increased pathogenicity in some hosts[3][5]. HA is the main target of neutralizing antibodies and is the protein most commonly used for influenza vaccine formulation and diagnostic assays due to its immunogenicity and subtype diversity (e.g., H5 in H5N1, H7 in H7N9)[1][4][5]. Its rapid antigenic evolution is a key challenge for durable immune protection and therapeutic targeting.
Inhibition of receptor binding (blocking HA-sialic acid interaction); Inhibition of membrane fusion (blocking conformational rearrangements required for viral entry); Induction of neutralizing antibodies (vaccination-mediated, targets HA head and stalk domains)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Avian influenza virus hemagglutinin protein (HA).